Elan (ELN) Slammed After Alzheimer Trial Endpoint Not Meet
Tweet
Share
E-mailGet Alerts ELN Hot Sheet
Join SI Premium – FREE
Elan Corporation, plc (NYSE: ELN) slammed after partner Pfizer Inc. (NYSE: PFE) announced that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 302).
Elan holds a 49.9% equity interest in JANSSEN Alzheimer Immunotherapy, and will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of AIP products.
Elan holds a 49.9% equity interest in JANSSEN Alzheimer Immunotherapy, and will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of AIP products.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
- Radiopharm trial advances to higher dose in HER2+ cancer study
- Keenova doses first patient in Phase 3 hammer toe drug trial
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
